News Column

REXAHN PHARMACEUTICALS, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits

January 21, 2014

Item 8.01 Other Events. On January 21, 2014 , Rexahn Pharmaceuticals, Inc. , a Delaware corporation ("Rexahn"), closed a registered direct offering of 19,047,620 shares of its common stock and warrants to purchase 4,761,905 shares of its common stock, which Rexahn sold in units consisting of one share of common stock and a five-year warrant to purchase 0.25 of a share of common stock at an exercise price of $1.28 per share of common stock for gross proceeds of $20,000,001 (the "Offering"). The Offering was previously announced in a Current Report on Form 8-K filed on January 15, 2014 . Item 9.01 Financial Statements and Exhibits. (d) Exhibits 5.1 Opinion of Hogan Lovells US LLP . 23.1 Consent of Hogan Lovells US LLP (included in Exhibit 5.1). 2 --------------------------------------------------------------------------------


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools